Leo Pharma Pursues Deals, New Drugs, To Compete With Big Pharma

 
• By John Davis
  
Generate a summary of this article
Listen to this article
Beta

Denmark’s specialty dermatology company, Leo Pharma, has globalized its infrastructure and is now investing in its internally and externally sourced product pipeline to help it compete with big pharma companies keen to move into the therapeutic area.

Leo Pharma AS is hoping a second-half 2017 launch of the new psoriasis therapy, Kyntheum (brodalumab) in Europe will add to its range of therapies for the condition, from topical ointments for mild disease to a systemic biologic for severe disease. The specialty dermatology company also expects its Phase IIb investigational atopic dermatitis therapy, tralokinumab, to become one of the leaders in a burgeoning atopic dermatitis sector.

Brodalumab, an interleukin-17 targeted monoclonal antibody, was licensed from AstraZeneca PLC for marketing in Europe, and is a key...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.